Minneslate Logo

HF862 (Legislative Session 94 (2025-2026))

Public postsecondary institutions required to maintain a supply of opiate antagonists on system campuses.

Related bill: SF164

AI Generated Summary

The proposed bill, authored by Representative Schomacker, mandates that public postsecondary education institutions in Minnesota must keep a supply of opioid antagonists, such as nasal naloxone, on their campuses. Specifically, the bill requires:

  1. Each campus location to maintain a supply of opioid antagonists as outlined in the specified sections of existing Minnesota law.
  2. A minimum of two doses of nasal naloxone available in each campus building.

The bill also directs the Minnesota Commissioner of Health to provide resources, including training materials like videos, to help these institutions implement an opioid antagonist emergency response plan. Furthermore, both the Board of Trustees of the Minnesota State Colleges and Universities and the Board of Regents of the University of Minnesota are encouraged to develop a model plan for the use, storage, and administration of opioid antagonists on their campuses.

This legislative action aims to enhance the safety and preparedness of educational institutions in dealing with opioid-related emergencies, thus safeguarding the health and well-being of students and staff on Minnesota's public postsecondary campuses.

Bill text versions

Actions

DateChamberWhereTypeNameCommittee Name
February 16, 2025HouseFloorActionIntroduction and first reading, referred toHigher Education Finance and Policy
February 23, 2025HouseFloorActionAuthors added
March 11, 2025HouseFloorActionAuthors added
March 16, 2025HouseFloorActionCommittee report, to adopt as amended and re-refer toHealth Finance and Policy
March 26, 2025HouseFloorActionAuthor added

Citations

 
[
  {
    "analysis": {
      "added": [
        "Institutions must now maintain a supply on campus for emergency use."
      ],
      "removed": [],
      "summary": "The bill requires higher education institutions to maintain opiate antagonists, modifying procedures under section 151.37 subdivision 12.",
      "modified": [
        "Specifies that at least two doses of nasal naloxone must be available."
      ]
    },
    "citation": "151.37 subdivision 12"
  },
  {
    "analysis": {
      "added": [],
      "removed": [],
      "summary": "The definition of opiate antagonists is referenced according to section 604A.04 subdivision 1.",
      "modified": [
        "Clarifies the term 'opiate antagonists' as per existing statutory definition."
      ]
    },
    "citation": "604A.04 subdivision 1"
  }
]

Sponsors